Alpha Cognition Inc ACOG

$8.34 +0.03 (0.36%)

Valuation

Market cap
181,628,000
Revenue TTM
$10,220,000
Net income TTM
$-20,670,000
PE ratio
0.00
Forward PE
—
Profit margin
-202.25%
Debt to equity
0.00

Trading

Volume
134,700
Avg volume
133,638
Day's range
$7.98 – $8.37
Shares out
21,778,000
Stochastic %K
38%
Beta
2.32
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-se...

Show more

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
858 344 4375
Website
https://www.alphacognition.com
Address
1452 Hughes Street, Suite 200, Grapevine, United States

Latest news

Stocktwits

biggercapital Oct 20, 12:48 PM
Alpha Cognition’s Billion Dollar Drug in the Making https://www.biggercapital.com/blog-posts/nbspzunveyl-alpha-cognitions-billion-dollar-drug-in-the-makingnbsp $ACOG
1 replies
JackCampbell Oct 20, 8:11 AM
$ACOG Essex specializes in small/micro-cap growth equities, focusing on identifying under-the-radar companies right before commercial acceleration. Their team targets revenue-generating healthcare/biotech firms with proprietary assets that are shifting toward profitability. Taking a brand-new 422k-share position indicates that $ACOG's commercial ramp and de-risked profile perfectly align with their fundamental growth strategy!
1 replies
JackCampbell Oct 20, 8:03 AM
$ACOG 2026-10-19 13F: Essex Investment Management Co Llc bought a fully new position of 422,858 shrs recently worth 3.806M USD!!
0 replies
SocioCobb Oct 19, 10:34 PM
$ACOG 👍
0 replies
Bioinvester001 Oct 15, 5:13 PM
$ACOG Really over sold. Adding.
1 replies
FlowerInTheCellar Oct 13, 6:56 PM
$ACOG https://www.businesswire.com/news/home/20261013519438/en/Alpha-Cognition-Announces-Publication-of-U.S.-Patent-Application-Relating-to-Proprietary-Manufacturing-Process-for-ZUNVEYL
0 replies
JackCampbell Oct 7, 3:02 PM
$ACOG step by step: https://finance.yahoo.com/healthcare/articles/alpha-cognition-present-zunveyl-benzgalantamine-123000060.html
0 replies
endrow Oct 7, 7:49 AM
$ACOG Crazy that ACOG is still this unknown. In a year this will be a billion dollar company and that just will be the start.
0 replies